Dublin, Aug. 17, 2017 -- The "Deuterated Drugs Formulations Therapeutics Markets Strategies" report has been added to Research and Markets' offering.
Deuterated Drugs: Products, Pipelines, Strategies, Therapeutics and Markets is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.
The study is designed to provide drug company decision makers, drug formulation developers, product designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for drugs that incorporate deuterium into the chemical structure of APIs to modify drug properties in vivo. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
Deuterated Drugs - What You Will Learn
- What deuterated drugs are currently FDA-approved or in late-stage development, what are their distinguishing properties, how are they marketed, and what are the therapeutic specifics?
- What are the major factors driving the development of deuterated drugs?
- What are the product strategies of deuterated drug developers?
- What is the size of the deuterated drug market today, who are the active sector participants, and what will the market look like in 2024?
- How important are formulator-developer-manufacturer relationships and what are the key alliances in the industry?
- What are the significant economic, technology, and regulatory factors affecting the market for deuterated drugs?
Report Value Matrix
- Managed Care Managers
- Management Consultants
- Financial Analysts
- Pharma Product Managers
- Device Suppliers
- Biotech Managers
- Drug Marketers & Strategists
- Clinical Managers
- Drug Distributors
- Pharma Regulators
- Product Developers
- Component Suppliers
- CMOs, CSOs
Key Topics Covered:
Executive Summary
Drug Therapy Market Dynamics
- Market Segments and Indications
- Competing Technologies
- Market Drivers
- Drug Re-positioning/Re-purposing
- Extending Patent Life
- Dosing Frequency & Patient Adherence
- Competitive Landscape
- Formulators/Developers
- Marketers
- Alliances
- Acquisitions
Deuterated Drug Therapeutics
- Formulation Technology
- Drug Property Kinetics
- Extending Dosing Intervals
- Addressing Unmet Therapeutic Needs
Selected Near-term Therapeutic Targets
- Neurotransmitter Regulation
- Transmembrane Conductance
- Kinase Inhibitors
- Anti-inflammatory
- Mitochondrial Function Modulation
- Antineoplastic
Deuterated Drugs - Near-term Therapeutic Market Analysis
- Addiction
- Autoimmune Diseases
- Hereditary
- Neurology
- Oncology
- Ophthalmology
Market Factors
- Regulations and Approvals
- Clinical Trials & End Points
- IP/Patent Factors
- Defensive Patent Strategies
- Healthcare Economics
Company Profiles
- Alkeus Pharmaceuticals
- Camargo
- Celgene
- CombiPhos
- Concert Pharmaceuticals
- DeuteRx
- Enanta Pharmaceuticals
- Invent Pharmaceuticals
- Lundbeck A/S
- Neuland Laboratories
- Otsuka Pharmaceuticals
- PharmatrophiX
- Protia LLC
- Retrotope
- Teva
For more information about this report visit https://www.researchandmarkets.com/research/q4fsx3/deuterated_drugs
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Drug Discovery


Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
OpenAI Explores Massive Funding Round at $750 Billion Valuation
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking.
Robinhood Expands Sports Event Contracts With Player Performance Wagers
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Shell M&A Chief Exits After BP Takeover Proposal Rejected
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 



